ZGNX · Zogenix, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 | Q3 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | $22.61M | $1.03M | $1.25M | - | $2.86M | - | - | - | $0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | $33.26M | $36.64M | $30.97M | - | $34.42M | $27.10M | $33.24M | - | $28.37M |
| SG&A | - | $39.56M | $33.88M | $31.27M | - | $24.58M | $24.43M | $21.32M | - | $15.76M |
| Total Operating Expenses | - | $76.48M | $74.22M | $65.49M | - | $293.97M | $41.85M | $48.16M | - | $293.97M |
| D&A | - | - | - | $2.37M | - | - | - | $357.0K | - | - |
| Operating Income | - | ($53.87M) | ($55.43M) | ($51.80M) | - | ($61.56M) | ($71.47M) | ($46.91M) | - | ($293.34M) |
| Interest Expense | - | $3.85M | $0 | - | - | - | - | - | - | - |
| Income Tax | - | $0 | $0 | - | - | $0 | ($17.43M) | - | - | - |
| Net Income | - | ($58.00M) | ($58.90M) | ($55.63M) | - | ($60.09M) | ($53.32M) | ($25.80M) | - | ($290.48M) |
| EPS - Basic | - | ($1.08) | ($0.96) | - | - | - | - | - | - | - |
| EPS - Diluted | - | ($1.08) | ($0.96) | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 | Q3 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $101.18M | $106.14M | $139.08M | $86.32M | $166.92M | $297.46M | $136.87M | $269.98M | $62.07M | $33.10M |
| Accounts Receivable | $10.14M | $9.49M | $7.70M | $6.12M | $3.82M | $0 | - | - | - | - |
| Inventory | $5.49M | $3.50M | $2.92M | $2.32M | $1.03M | $1.01M | $475.0K | - | - | - |
| Accounts Payable | $22.00M | $12.11M | $10.83M | $11.96M | $11.95M | $7.22M | $8.52M | $7.89M | $7.98M | $7.55M |
| Current Assets | $354.57M | $375.46M | $416.39M | $454.73M | $522.17M | $565.39M | $426.56M | $478.58M | $287.24M | $292.27M |
| Total Assets | $468.49M | $496.99M | $540.07M | $580.96M | $651.13M | $692.05M | $555.11M | $606.91M | $414.25M | $420.37M |
| Current Liabilities | $97.69M | $78.43M | $69.34M | $58.53M | $82.72M | $92.30M | $93.07M | $88.81M | $95.39M | $97.44M |
| Long-term Debt | $158.16M | - | - | - | $149.35M | - | - | - | $0 | - |
| Total Liabilities | $289.52M | $272.69M | $267.21M | $259.68M | $281.46M | $269.95M | $149.96M | $156.40M | $169.19M | $169.77M |
| Stockholders' Equity | $178.97M | $224.30M | $272.86M | $321.28M | $369.67M | $422.09M | $405.14M | $450.51M | $245.06M | $250.59M |
| Retained Earnings | ($1.55B) | ($1.50B) | ($1.44B) | ($1.38B) | ($1.32B) | ($1.25B) | ($1.19B) | ($1.14B) | ($1.12B) | ($1.06B) |
Cash Flow
| Line item | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 | Q3 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | ($53.86M) | - | - | - | ($52.49M) | - | - |
| Investing Cash Flow | - | - | - | ($10.85M) | - | - | - | $37.22M | - | - |
| Financing Cash Flow | - | - | - | ($15.89M) | - | - | - | $223.18M | - | - |
| CapEx | - | - | - | $87.0K | - | - | - | $193.0K | - | - |
| Free Cash Flow | - | - | - | ($53.95M) | - | - | - | ($52.68M) | - | - |
Ratios
| Metric | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 | Q3 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | -238.3% | -5371.2% | -4147.6% | - | -2152.4% | - | - | - | - |
| EBITDA margin | - | - | - | -3958.3% | - | - | - | - | - | - |
| Net margin | - | -256.5% | -5707.0% | -4454.0% | - | -2101.0% | - | - | - | - |
| Free cash flow margin | - | - | - | -4319.1% | - | - | - | - | - | - |
| FCF / Net income | - | - | - | 0.97 | - | - | - | 2.04 | - | - |
| R&D / Revenue | - | 147.1% | 3550.8% | 2479.5% | - | 1203.7% | - | - | - | - |
| SG&A / Revenue | - | 175.0% | 3283.2% | 2503.8% | - | 859.5% | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | - | -11.7% | -10.9% | -9.6% | - | -8.7% | -9.6% | -4.3% | - | -69.1% |
| Return on equity | - | -25.9% | -21.6% | -17.3% | - | -14.2% | -13.2% | -5.7% | - | -115.9% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 3.63 | 4.79 | 6.01 | 7.77 | 6.31 | 6.13 | 4.58 | 5.39 | 3.01 | 3.00 |
| Quick ratio | 3.57 | 4.74 | 5.96 | 7.73 | 6.30 | 6.11 | 4.58 | 5.39 | 3.01 | 3.00 |
| Cash ratio | 1.04 | 1.35 | 2.01 | 1.47 | 2.02 | 3.22 | 1.47 | 3.04 | 0.65 | 0.34 |
| Leverage | ||||||||||
| Debt / Equity | 0.88 | - | - | - | 0.40 | - | - | - | 0.00 | - |
| Debt / Assets | 0.34 | - | - | - | 0.23 | - | - | - | 0.00 | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | -14.0x | - | - | - | - | - | - | - | - |
| Equity multiplier | 2.62 | 2.22 | 1.98 | 1.81 | 1.76 | 1.64 | 1.37 | 1.35 | 1.69 | 1.68 |
| Liabilities / Assets | 0.62 | 0.55 | 0.49 | 0.45 | 0.43 | 0.39 | 0.27 | 0.26 | 0.41 | 0.40 |
| Efficiency | ||||||||||
| Asset turnover | - | 0.05 | 0.00 | 0.00 | - | 0.00 | - | - | - | 0.00 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | 153d | 2724d | 1788d | - | 0d | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | 690.6% | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | 28.0% | -13.1% | -32.9% | - | -20.7% | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | 12.5% | 22.4% | -10.4% | - | 79.0% | -75.2% | -22.6% | - | -561.8% |
| Net income growth (YoY) | - | 3.5% | -10.4% | -115.6% | - | 79.3% | -41.2% | 26.7% | - | -587.3% |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | -2.4% | - | - | - | -79.4% | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -51.6% | -46.9% | -32.7% | -28.7% | 50.8% | 68.4% | -13.0% | -9.3% | -53.1% | -53.5% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Geographic
$74.74M totalUS$65.68M · 87.9%
Europe$9.06M · 12.1%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing ZOGENIX against the 5 most active filers in the same SIC group.